"I believe that is the abstract from a presentation - poster? - that was given at the recent EDTA-ERA meeting."  

That ERA-EDTA abstract was awarded one of the absolute best abstract awards for the ERA-EDTA conference (see page 8). However, I don't know if this was a poster or an oral presentation, or if it was actually presented or withdrawn; I am having trouble determining this on the ERA-EDTA website and I don't see the poster/presentation on the RVX website.

"Interesting to note that: "Consistent with phase 2, BETonMACE saw serum ALP reduced by 6.8 U/L with apabetalone (n=1082) vs placebo (n=1070; p<0.001) at 24 weeks."

Yes, this was published in the JAMA 2020 BETonMACE paper. "In the apabetalone group, alkaline phosphatase level was reduced from 83.3 U/L at baseline to 76.5 U/L at 2 weeks and 74.3 U/L at 24 weeks. In the placebo group, alkaline phosphatase levels decreased from 81.9 U/L at baseline to 80.2 and 79.5 U/L, respectively, at 2 and 24 weeks."

The November 2019 corporate update, but not the JAMA paper, also presented data at 100 weeks (see slides 53 and 54).

BDAZ